Table of Contents:
I. I. Enhancing Health Disparities Research Related to Substance Use and Addiction: Research Gaps and Opportunities
II. II. New Funding Opportunities
I. I. Enhancing Health Disparities Research Related to Substance Use and Addiction: Research Gaps and Opportunities
We invite you to attend the Enhancing Health Disparities Research Related to Substance Use and Addiction: Research Gaps and Opportunities Virtual Meeting.
When:
February 16th 1:00 pm to 5:00 pm EST
February 17th 1:00 pm to 5:00 pm EST
Where: Zoom Webinar
Please register here: https://seiservices.zoom.us/webinar/register/WN_phXk-hLdT9awpWTCGO9W9w
Agenda
Please see attached agenda for a full list of topics, questions to think about, speakers and panelists.
Day 1: SOCIAL DETERMINANTS OF HEALTH
Day 2: HARNESSING BASIC SCIENCE TO UNDERSTAND RACIAL DISPARITIES AND THE IMPACT OFRACISM
Workshop Description
The goals of this virtual meeting are to discuss research gaps on racial inequities in substance use and addiction and to inform NIDA’s commitment to this area by identifying short- and long-term plans for enhancing the research portfolio. Discussion will center on research in areas where there are known racial/ethnic inequities; and where research has the greatest potential to reduce those disparities. These include, but are not limited to, persistent health disparities related to substance use, addiction, and related outcomes; a lack of attention to research questions most salient to underrepresented communities; and existing system bias in the scientific enterprise. The overarching goal of the Research Gaps and Opportunities Workgroup is to engage the scientific community in identifying research priorities that can inform NIDA programs/funding opportunities and ultimately reduce health disparities and improve outcomes.
Questions
Please contact Caitlin Dudevoir at CDudevoir@leedmci.com
II. II. New Funding Opportunities:
· High-throughput Discovery and Validation of Novel Signal Transducers or Small Molecules that Modulate Opioid or other Substance Use Disorder Relevant Pathways (R01 - Clinical Trials Not Allowed)
(RFA-DA-22-006)
National Institute on Drug Abuse
Application Receipt Date(s): September 15, 2021
· Exploratory studies to investigate mechanisms of HIV infection, replication, latency, and/or pathogenesis in the context of substance use disorders (R61/R33 - Clinical Trial Not Allowed)
(RFA-DA-22-004)
National Institute on Drug Abuse
Application Receipt Date(s): July 14, 2021
· NIH Blueprint for Neuroscience Research: Tools and Technologies to Explore Nervous System Biomolecular Condensates (R21 Clinical Trial Not Allowed)
(RFA-DA-22-008)
National Institute on Drug Abuse
National Center for Complementary and Integrative Health
National Eye Institute
National Institute on Aging
National Institute on Alcohol Abuse and Alcoholism
National Institute of Biomedical Imaging and Bioengineering
Eunice Kennedy Shriver National Institute of Child Health and Human Development
National Institute of Dental and Craniofacial Research
National Institute of Environmental Health Sciences
National Institute of Mental Health
National Institute of Neurological Disorders and Stroke
Office of Behavioral and Social Sciences Research
Application Receipt Date(s): September 15, 2021
The National Institute on Drug Abuse at the National Institutes of Health is an agency of the United States Department of Health and Human Services TO UNSUBSCRIBE: send email to listserv@list.nih.gov Copy and paste UNSUBSCRIBE NIDA_NEURO_SCIENCE-L
No comments:
Post a Comment